The price of Better Therapeutics Inc (NASDAQ:BTTX) shares last traded on Wall Street rose 23.60% to $0.21.
Based on available information, 2 analysts follow Better Therapeutics Inc (NASDAQ:BTTX). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $9.00 and a low of $1.50, we find $5.25. Given the previous closing price of $0.17, this indicates a potential upside of 2988.24 percent. BTTX stock price is now -29.42% away from the 50-day moving average and -72.87% away from the 200-day moving average. The market capitalization of the company currently stands at $9.95M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
Among analysts, 0 rate the stock a hold while 2 rate it a buy. Brokers who have rated the stock have averaged $5.25 as their price target over the next twelve months.
With the price target of $17, Chardan Capital Markets recently initiated with Buy rating for Better Therapeutics Inc (NASDAQ: BTTX).
In other news, PERRY DAVID P, Executive Chairman bought 1,233,045 shares of the company’s stock on Jul 27. The stock was bought for $900,000 at an average price of $0.73. Upon completion of the transaction, the Executive Chairman now directly owns 13,030,393 shares in the company, valued at $2.74 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 27, Director Parker Geoffrey M. bought 685,025 shares of the business’s stock. A total of $500,000 was incurred on buying the stock at an average price of $0.73. This leaves the insider owning 1,028,055 shares of the company worth $0.22 million. A total of 50.83% of the company’s stock is owned by insiders.
A candlestick chart of Better Therapeutics Inc (NASDAQ: BTTX) showed a price of $0.1700 on Friday morning. During the past 12 months, Better Therapeutics Inc has had a low of $0.14 and a high of $1.61. The fifty day moving average price for BTTX is $0.2896 and a two-hundred day moving average price translates $0.7684 for the stock.
The latest earnings results from Better Therapeutics Inc (NASDAQ: BTTX) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.15, beating analysts’ expectations of -$0.19 by 0.04. This compares to -$0.48 EPS in the same period last year. The company reported revenue of $5.34 million for the quarter, compared to $11.0 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -51.43 percent.
Better Therapeutics Inc(BTTX) Company Profile
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company’s lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company’s clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.
